P4HB and plasma cell myeloma: When patients parsed by clinical groups as newly diagnosed myeloma (NDMM), early relapse (ERMM, 1–3 prior lines of therapy), or late relapse (LRMM > 3 prior lines of therapy) were analyzed separately, high PDIA1 expression conferred inferior survival in ERMM and LRMM but not NDMM (Figure 1B–D).